GRAYBUG VISION INC (GRAY) Stock Price, Forecast & Analysis
USA - NASDAQ:GRAY - US38942Q1031 - Common Stock
GRAY Key Statistics, Chart & Performance
The current stock price of GRAY is 5.5 USD. In the past month the price decreased by -37.39%. In the past year, price decreased by -69.78%.
GRAY Latest News, Press Relases and Analysis
GRAY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.62 | 970.39B | ||
| JNJ | JOHNSON & JOHNSON | 18.88 | 471.87B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.09B | ||
| PFE | PFIZER INC | 7.83 | 142.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.95B | ||
| ZTS | ZOETIS INC | 19.06 | 53.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.6 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.97 | 10.48B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.07B |
Related stock screener links
About GRAY
Company Profile
Graybug Vision Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Redwood City, California and currently employs 8 full-time employees. The company went IPO on 2020-09-25. Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases. The firm's products include GB-102 and GB-401. GB-102 is a lead product designed to provide pan-vascular endothelial growth factor (VEGF) inhibition for six months or longer while minimizing fluctuations in retinal thickness in between treatments. GB-102 is a once-every-six month intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD). The firm is also evaluating and developing GB-102 for the treatment of diabetic retinopathy (DR). GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor designed to provide a controlled release of the active drug to maintain reduced intraocular pressure (IOP) for six months or longer after a single injection for the treatment of primary open-angle glaucoma.
Company Info
GRAYBUG VISION INC
274 Redwood Shores Parkway, P.O. Box 144
Redwood City CALIFORNIA 94065 US
CEO: Frederic Guerard
Employees: 8
Phone: 16504872800.0
GRAYBUG VISION INC / GRAY FAQ
Can you describe the business of GRAYBUG VISION INC?
Graybug Vision Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Redwood City, California and currently employs 8 full-time employees. The company went IPO on 2020-09-25. Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases. The firm's products include GB-102 and GB-401. GB-102 is a lead product designed to provide pan-vascular endothelial growth factor (VEGF) inhibition for six months or longer while minimizing fluctuations in retinal thickness in between treatments. GB-102 is a once-every-six month intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD). The firm is also evaluating and developing GB-102 for the treatment of diabetic retinopathy (DR). GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor designed to provide a controlled release of the active drug to maintain reduced intraocular pressure (IOP) for six months or longer after a single injection for the treatment of primary open-angle glaucoma.
What is the stock price of GRAYBUG VISION INC today?
The current stock price of GRAY is 5.5 USD. The price decreased by -10.8% in the last trading session.
Does GRAYBUG VISION INC pay dividends?
GRAY does not pay a dividend.
What is the ChartMill rating of GRAYBUG VISION INC stock?
GRAY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is GRAYBUG VISION INC (GRAY) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GRAY.
What is GRAYBUG VISION INC worth?
GRAYBUG VISION INC (GRAY) has a market capitalization of 617.26K USD. This makes GRAY a Nano Cap stock.
What is the ownership structure of GRAYBUG VISION INC (GRAY)?
You can find the ownership structure of GRAYBUG VISION INC (GRAY) on the Ownership tab.
GRAY Technical Analysis
GRAY Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GRAY. GRAY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GRAY Financial Highlights
Over the last trailing twelve months GRAY reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS increased by 1.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
GRAY Forecast & Estimates
6 analysts have analysed GRAY and the average price target is 42.84 USD. This implies a price increase of 678.91% is expected in the next year compared to the current price of 5.5.